Clinically, patients with COVID-19 without substantial neurological symptoms showed significantly higher plasma concentrations of GFAP, a marker of astrocytic activation, and of NfL and total tau, markers of axonal damage and neuronal degeneration, compared with controls [52]. This evidence concerns the gene NEFL and COVID-19.